Affimed N.V

General information
Affimed N.V
Gottlieb-Daimler-Straße 2
68165 Mannheim, Baden-Württemberg
Germany

Contact person: Shawn M. Leland, Chief Executive Officer
Company main phone: +49 (621) 560030
Company main fax:  +49 (621) 56003649
Website:  https://www.affimed.com
Year founded:2000
Source of foundation:Spin-off from public institution / NPO
Name of foundation source:German Cancer Research Centre (DKFZ)
No. of employees: Worldwide:  76
Corporate description / mission:
Affimed is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company’s proprietary ROCK® platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK® platform predictably generates customized innate cell engager (ICE®) molecules, which use patients’ immune cells to destroy tumor cells.
State of ownership: Publicly listed on stock exchange
Headquarters: HQ: Yes
IPO (year): 2014
Categorization
Sector:
  • Biotechnology - Therapeutics and Diagnostics
Subsector:
  • Antibodies
  • Cell therapy
  • Immunotherapy
Primary therapeutic areas:
  • Neoplasms / cancer / oncology
Business model:
  • Out-licensing
  • R&D
Customer segments:
  • Large biotech & big pharma
  • Small biotech
Summary Products / Services / Technologies
Number of Biotech Products
Pre-clinical:4
Phase I:2
Phase II:7
Description of products:
AFM13
AFM24
AFM28
AFM32, etc.
Technology used:
ROCK® Platform
Financing details
Market cap. / valuation:USD 15.32M
Collaborations & Clients
Partnering strategy / collaborations:
Genentech
Artiva
Roche
Merck, etc.
X